Gastric cancer is the fourth most common malignancy and the second leading cause of cancer death amongst men and women worldwide. Both genetic and environmental factors are proposed to contribute to gastric tumorigenesis. For example, germline E-cadherin mutations result in Hereditary Diffuse Gastric Cancer, an inherited cancer predisposition syndrome. Meanwhile, environmental acquisition of H. pylori infection is a major cause of sporadic intestinal-type gastric cancer. The study of gastric cancer has been hampered by the lack of adequate model systems, an incomplete investigation of the somatic mutations that contribute to gastric cancer, and an insufficient evaluation of the gastric stem cell compartment's role in tumorigenesis. In my preliminary efforts I have developed a robust primary gastric explant culture system that enables the long-term propagation and multi-lineage differentiation of gastric epithelium that can further undergo successful oncogenic transformation, thus representing the first-ever development of invasive carcinoma from primary gastric epithelium in the in vitro setting. The project and experiments I propose in this project encompass an integrated and collaborative approach aimed at 1) developing a robust in vitro gastric cancer model, 2) validating a novel oncogene amplification (FGFR2) in human gastric cancer and assessing the prevalence of this finding in sporadic and familial gastric cancers, and 3) confirming the roles of the gastric stem cell compartment in the development of gastric cancer. This project integrates cell biology, human genetics and mouse knockout approaches to gain insight into gastric cancer tumorigenesis and specifically, E-cadherin-dependent tumorigenesis. As a Medical Oncologist with PhD training in molecular biology and oncological science, I have a deep and long-standing interest in the molecular pathogenesis of solid tumors including gastric cancer. I propose to pursue mentored research in the laboratory of Dr. Calvin Kuo at the Stanford University Medical School in order to develop the required skills and ability to become a successful, independent investigator. In addition to scientific mentoring by Dr. Kuo, I will receive guidance by Dr. James Ford and a supervisory committee with expertise in genomics, cancer biology and translational research. I believe this project will lead to the identification o new gastric cancer oncogenes that will become immediate targets for novel therapeutics and for application of previously-developed small molecule inhibitors. I intend to devote 90% of my effort to this project in the laboratory under the mentorship of Dr. Kuo. The remainder of my time will be spent working with Dr. James Ford, my co-mentor, in the GI Oncology Clinic at the Stanford Cancer Center where I will continue to see gastric cancer patients in addition to pursuing didactic training, attending national meetings and preparing presentations and manuscripts describing my work. My goal remains to obtain an appointment in a Division of Medical Oncology as a tenure-track academic physician scientist who pursues innovative research capable of bringing novel therapeutic options to the clinic.

Public Health Relevance

Gastric cancer is a major worldwide health concern that has been historically underfunded and scientifically under-investigated. This project seeks to investigate the causes of gastric cancer by identifying and validating novel cancer-causing genes which could then be exploited to develop novel treatments for this disease. This proposal describes the recent development of a unique in vitro method for studying gastric cancer and seeks to leverage this advancement to functionally validate both newly identified cancer-causing genes, and the contribution of stem cells to the development of gastric cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
4K08CA166512-05
Application #
9129610
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Lim, Susan E
Project Start
2012-09-17
Project End
2017-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
5
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Ihc Health Services, Inc.
Department
Type
DUNS #
072955503
City
Salt Lake City
State
UT
Country
United States
Zip Code
84111
Haslem, Derrick S; Chakravarty, Ingo; Fulde, Gail et al. (2018) Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. Oncotarget 9:12316-12322
Greer, Stephanie U; Nadauld, Lincoln D; Lau, Billy T et al. (2017) Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. Genome Med 9:57
Haslem, Derrick S; Van Norman, S Burke; Fulde, Gail et al. (2017) A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. J Oncol Pract 13:e108-e119
Nadauld, Lincoln D; Garcia, Sarah; Natsoulis, Georges et al. (2014) Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol 15:428
Li, Xingnan; Nadauld, Lincoln; Ootani, Akifumi et al. (2014) Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med 20:769-77
Nadauld, Lincoln D; Ford, James M (2013) Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol 31:838-9
Nadauld, Lincoln D; Ford, James M (2012) Family history as a positive prognostic factor in gastric cancer. J Clin Oncol 30:683-4
Nadauld, Lincoln; Regan, John F; Miotke, Laura et al. (2012) Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Transl Med (Sunnyvale) 2: